[HTML][HTML] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic …

CQ Huang, Y Min, SY Wang, XJ Yang, Y Liu, B **ong… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Objectives The therapeutic efficacy of cytoreductive surgery (CRS) plus hyperthermic
intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis (PC) from …

Surgical treatment of metastatic colorectal cancer

J Chakedis, CR Schmidt - Surgical Oncology Clinics, 2018 - surgonc.theclinics.com
Metastatic disease occurs in half of people with colorectal cancer (CRC). Metastasis spread
through hematogenous or lymphangitic routes and may occur in lymph nodes, liver, lung …

Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

S Hallam, R Tyler, M Price, A Beggs, H Youssef - BJS open, 2019 - academic.oup.com
Background Up to 15 per cent of colorectal cancers present with peritoneal metastases
(CPM). Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS+ HIPEC) …

Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer

C Yurttas, G Hoffmann, A Tolios, SP Haen… - Journal of Clinical …, 2018 - mdpi.com
Background: Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal
chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy …

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer

GA Simkens, KP Rovers, SW Nienhuijs… - Cancer management …, 2017 - Taylor & Francis
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a
viable option for selected patients with peritoneal metastases (PM) from colorectal origin …

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal …

V Narasimhan, S Tan, J Kong, T Pham… - Colorectal …, 2020 - Wiley Online Library
Aim Peritoneal metastases from colorectal cancer confer the worst survival among all
metastatic sites. The adoption of cytoreductive surgery (CRS) with hyperthermic …

[HTML][HTML] Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review—past, present and future

A Dehal, JJ Smith, GM Nash - Journal of gastrointestinal oncology, 2016 - ncbi.nlm.nih.gov
Peritoneal carcinomatosis (PC) has historically been considered a terminal condition with
merely palliative treatment achieving a survival rate measured in months. Cytoreductive …

Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases

KP Rovers, C Bakkers, FN Van Erning… - JAMA …, 2020 - jamanetwork.com
Importance To date, there are no data on the value of adjuvant systemic chemotherapy
following up-front resection of isolated synchronous colorectal peritoneal metastases …

[HTML][HTML] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection

J Esquivel - Journal of gastrointestinal oncology, 2016 - ncbi.nlm.nih.gov
Background Chemotherapy hyperthermic intraperitoneal chemotherapy (HIPEC) is playing
an ever increasing role in the management of colorectal cancer (CRC) with peritoneal …

Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review

KP Rovers, GA Simkens, CJ Punt, S van Dieren… - Critical Reviews in …, 2017 - Elsevier
Abstract Background/Purpose Despite its widespread use, no randomised studies have
investigated the value of perioperative systemic therapy as adjunct to cytoreduction and …